Introduction: A subset of patients with potentially resectable clinical stage IIIA NSCLC are managed with trimodality therapy. However, little data exist to guide the timing of surgery after neoadjuvant therapy. This study examined whether the time interval between neoadjuvant chemoradiation (NCRT) and surgical resection affects overall survival.
Introduction
Patients presenting with locally advanced NSCLC represent a significant clinical challenge given the relatively poor prognosis associated with this stage of disease. In approximately one-third of all patients with NSCLC the disease is locally advanced when diagnosed, with the 5-year survival ranging from 7% to 19%. 1 Currently, neoadjuvant chemoradiation therapy followed by surgery is an accepted treatment strategy for selected stage IIIA patients with resectable tumors and limited mediastinal node (N2) involvement. [2] [3] [4] However, randomized trials have not demonstrated a significant survival advantage of trimodality therapy compared with definitive chemoradiation therapy. 3, 5, 6 Despite this, trimodality therapy may have some advantages, particularly when a lobectomy can be performed. In particular, the optimal interval to surgery (ITS) after completion of neoadjuvant chemoradiation (NCRT) has not been well explored.
Previous studies have demonstrated that NCRT is associated with elevated rates of adverse postoperative events related to hematologic toxicity and pulmonary injury. 3 To reduce the morbidity associated with operating on patients with fibrosis or pneumonitis, randomized trials studying the use of NCRT in locally advanced NCSLC support minimizing the interval from completion of NCRT (usually the final dose of radiotherapy) to surgery. 3, 4, 7, 8 However, there have been no studies demonstrating that an increased time interval between NCRT and surgery is associated with inferior survival.
Recent data from studies in which esophageal and rectal cancer were managed with NCRT have demonstrated that prolonged interval between NCRT and surgery may be associated with enhanced tumor downstaging and an increased likelihood of complete pathologic response, which was correlated with improved survival for patients with rectal cancer. [9] [10] [11] This observation is thought to occur because the facilitation of mitotic death and tumor regression by radiation therapy is a relatively slow process. 12 To date, it is unknown whether patients with NSCLC treated with NCRT will also benefit from a longer interval to surgery for this reason.
Additionally, treatment with radiation therapy is known to impair the diffusion capacity of the lung for carbon monoxide. 13 In support of prolonging ITS, limited observational data have suggested resolution of this effect 4 to 6 weeks after completion of treatment. 13, 14 As a result, recommendations to wait at least 4 to 6 weeks after radiation therapy to perform surgery for NSCLC are common practice.
Despite these recommendations, the optimal timing of surgery for patients who undergo trimodality therapy is unclear and seems to largely rest on a balance between the risks and benefits of chemoradiation therapy in patients with locally advanced NSCLC. The primary objective of this study was to examine whether the ITS after completion of NCRT correlates with survival outcomes in patients with clinical stage IIIA, T1-3 N2 NSCLC.
Materials and Methods

Data Source
A retrospective analysis was performed using the National Cancer Data Base (NCDB), a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The NCDB integrates cancer registry records from more than 1500 accredited hospitals and captures approximately 70% of newly diagnosed cancers in the United States. 15 Variables recorded in the database include patient demographics, Charlson-Deyo comorbidity score, socioeconomic status, tumor characteristics, and the first course of therapy, which is defined as all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. Recurrence rates along with treatments delivered or withheld because of recurrent or progressive disease and other treatment modifications are not recorded. Details of anatomic treatment location, dose, number of fractions, and radiation technique are recorded, but details regarding chemotherapy drug names, dose, treatment duration, and performance status are not. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for either the analytic or statistical methodology used, nor for the conclusions drawn from these data by the investigator. This study was granted an exemption by the Yale Human Investigation Committee under federal regulations covering research involving the study of existing data, documents, records, pathological specimens, or diagnostic specimens if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified directly or through identifiers linked to the subjects.
Cohort Definition
Records for patients in whom clinical T1-3 NSCLC with N2 involvement was diagnosed between 2004 and 2012 were obtained from the NCDB participant user file. Patients with clinical T4 N0-1 and clinical stage IIIB were excluded from this analysis because only a small subset of these patients are considered operable (namely those without pleural effusion; superior vena cava syndrome; or invasion of the heart, esophagus, or vertebra as defined by previous trials). 4, 5 Because the NCDB does not record the location of tumor invasion or distinguish between operable and inoperable cases, they were excluded to avoid the inclusion of confounding data. Selected patients were required to have undergone either lobectomy, sublobar resection, or pneumonectomy (Facility Oncology Registry Data Standards code 21-70). Those with stage IV disease were excluded along with patients whose multimodality treatment sequence was unknown. Inclusion and exclusion criteria are summarized in Figure 1 . Patients who underwent salvage therapy, defined as surgical resection performed later than 3 months after NCRT, were excluded. Entries with unknown margin status and unknown vital status were also excluded. Patients were required to undergo multiagent chemotherapy and radiation therapy within 3 weeks of each other to be categorized as undergoing concurrent NCRT. 16, 17 The study cohort was limited to patients receiving 40 to 60 Gy of thoracic radiation, a range considered standard for neoadjuvant treatment. [17] [18] [19] February 2017
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Variables
To assess socioeconomic status, patients were dichotomized by an estimated median income of at least $63,000 versus less than $63,000, urban location (county population >250,000), and insurance status (private versus nonprivate). Furthermore, treatment facility types, which are assigned in the NCDB according to the Commission on Cancer accreditation category on the basis of annual case volume and available oncology services, were dichotomized as academic or nonacademic. Academic facilities included centers that provided postgraduate medical education in at least four areas, including internal medicine and general surgery, and had accessions to more than 500 new cancer cases each year. Nonacademic facilities included community cancer programs (defined as centers with accessions to more than 100 but fewer than 500 newly diagnosed cancer cases per year as well as optional resident training) and comprehensive community cancer programs (defined as centers with accessions to more than 500 newly diagnosed cancer cases per year and offered optional resident training). To characterize comorbidity status, patients were categorized by the Charlson-Deyo variation of the Charlson comorbidity index, listed as 0,1, or 2 by the NCDB. 20 Other tumor and patient characteristics were categorized as follows: histologic type was categorized as squamous cell cancer, adenocarcinoma, large cell carcinoma, or other; race was categorized as white, black, or other; and postoperative margins were categorized as negative or positive. Age, total radiation dose, and tumor size were treated as continuous variables.
The ITS is not directly provided by the NCDB. This interval was calculated in the following manner:
where S days represents the number of days from diagnosis to surgery, RT days represents the number of days from diagnosis to the start of radiotherapy, and RT duration represents the duration of radiation therapy in days. These three variables are all provided by the NCDB. This calculation derives the postradiation interval to surgery precisely in units of days. All patients underwent concurrent chemotherapy along with radiation therapy, but the duration of chemotherapy is not provided by the NCDB and could not be incorporated into the ITS formula.
The study cohort was categorized by the interval between completion of NCRT and surgery: 0 to 3 weeks, greater than 3 and less than or equal to 6 weeks, greater than 6 and less than or equal to 9 weeks, greater than 9 and less than or equal to 12 weeks after NCRT. The median ITS of the study cohort was 6 weeks. This fact, along with the understanding that most trials wait approximately 3 to 6 weeks from the completion of radiation therapy to proceed, formed the basis for stratifying patients according to the aforementioned quartiles. In the Intergroup 0139 trial, which is one of the more recognized studies examining trimodality therapy compared with definitive chemoradiation therapy in NSCLC, patients were confirmed to have stable disease 2 to 4 weeks after radiation before proceeding to surgery 3 to 5 weeks after radiation. 3, 5 In the German Lung Cancer Group trial, patients were assessed for response to induction therapy and allowed to proceed to surgery 4 to 6 weeks after radiation. 4 Thus, the study design in this report will help determine whether patients in the 3 to less than 6 weeks category have different outcomes than patients in the other categories.
Statistical Analysis
To study differences in patient characteristics among the four ITS quartiles, categorical variables were compared using c2 tests whereas continuous variables were compared using independent sample t tests. In the comparative survival analysis, the primary end point was overall survival (OS), which was defined as the time from diagnosis to death. Univariate survival analysis was conducted by the Kaplan-Meier method and log-rank test. Univariate Cox proportional hazards regression was used to determine significant contributors to OS differences, and the proportional hazards assumption was checked graphically by using log-log survival plots.
From the results of the univariate analyses, a multivariate Cox proportional hazards model was built using a backward stepwise elimination method. Variables were included in the multivariate analysis only if found to be associated with survival (p < 0.10) on univariate analysis. Margin status and length of stay were not included in the multivariate analyses on account of potentially confounding collinearity with other included variables. All analyses were performed using STATA SE 13.1 (StataCorp LP, College Station, TX).
Results
Patient Characteristics
There were 1623 patients identified who underwent concurrent NCRT followed by surgery. The median interval to surgery was 40 days (interquartile range 31-50) (mean 41.1 ± 15.4 days). The reference group consisted of 7.9% of patients who underwent surgery 0 to 3 weeks after NCRT (n ¼ 129); 50.5% who underwent surgery greater than 3 and less than or equal to 6 weeks after NCRT (n ¼ 819), 31.9% who underwent surgery greater than 6 and less than or equal to 9 weeks after surgery (n ¼ 519), and 9.6% who underwent surgery greater than 9 and less than or equal to 12 weeks after surgery (n ¼ 156).
Comparisons of patient characteristics between the quartiles are listed in Table 1 and pertinent data are as follows. Patients with an ITS of greater than 6 and less than or equal to 9 weeks (median total radiation dose received: 50.0 Gy) and greater than 9 and less than or equal to 12 weeks (median total radiation dose received 50.0 Gy) received significantly higher therapeutic doses of radiation than those who underwent surgery 0 to 3 weeks (median total radiation dose received: 46.0 Gy) (p < 0.01 and p ¼ 0.023 respectively) after NCRT (see Table 1 ). Similarly, a trend (p < 0.10) toward increased 90-day mortality was seen in patients in the greater than 6 and less than or equal to 9 weeks (90-day mortality 8.7%) and greater than 9 and less than or equal to 12 weeks quartiles (90-day mortality 9.6%) compared with patients in the 0 to 3 weeks reference group (90-day mortality 3.9%) (p ¼ 0.068 and p ¼ 0.059, respectively). No difference in 30-day mortality was observed between groups. The percentage of patients who underwent a pneumonectomy instead of a lobectomy or a sublobar resection was also lower in the greater than 6 and less than or equal to 9 weeks cohort (14.3%) and in the greater than 9 and less than or equal to 12 weeks cohorts (12.1%) compared with in the 0 to 3 weeks cohort (22.5%) (p ¼ 0.026 and p ¼ 0.021, respectively (see Table 1 ). Unfortunately, the NCDB does not provide the reasoning behind the choice of pneumonectomy, lobectomy, or sublobar resection in patients. Location of tumor and other indicators that may play a role in the selection of one surgical procedure over another were also not available. Finally, although all patients underwent multiagent concurrent chemotherapy in addition to radiation therapy, the NCDB does not provide specific information about chemotherapy regimens, drug names, or dosing, the details of which may affect outcomes and influence choice of surgery.
OS
Kaplan-Meier curves demonstrated the trends in survival among the four quartiles and are shown in Figure 2 . The reference group was set as those with an ITS of 0 to 3 weeks. In the univariate Cox regression, there was no significant difference in OS between the 0 to 3 weeks cohort (median OS 60.7 months) and the greater than 3 and less than or equal to 6 weeks cohort (median OS 45.2 months) (p ¼ 0.141). However, a trend toward decreasing OS was observed in patients with an ITS of greater than 6 and less than or equal to 9 weeks (median OS 44.1 months) (p ¼ 0.069). Those who underwent surgery greater than 9 and less than or equal to 12 weeks after NCRT (median OS 36.1 months) fared significantly worse than those who underwent surgery 0 to 3 weeks after NCRT (p ¼ 0.041 [ Table 2 ]). It is important to consider that a significantly higher percentage of patients in the greater than 6 and less than or equal to 9 weeks and greater than 9 and less than or equal to 12 weeks categories had a lobectomy instead of a pneumonectomy than in the 0 to 3 weeks category. In the multivariate Cox regression, which accounted for the fact that receipt of a lobectomy was associated with a more favorable survival outcome compared with receipt of a pneumonectomy, patients with an ITS of greater than 6 and less than or equal to 9 weeks (hazard ratio [HR] ¼ 1.33, 95% confidence interval [CI]: 1.01-1.76, p ¼ 0.043) and greater than 9 and less than or equal to 12 weeks (HR ¼ 1.44, 95% CI: 1.04-2.01, p ¼ 0.030) fared significantly worse than patients who underwent surgery 0 to 3 weeks after NCRT (see Table 2 ). There was no significant difference in OS between patients who had surgery greater than 3 and less than or equal to 6 weeks after NCRT (HR ¼ 1.26, 95% CI: 0.94-1.67, p ¼ 0.107) and 0 to 3 weeks after NCRT. Of note, the median ITS for the reference group (0 to 3 weeks) was 18 days (interquartile range [14] [15] [16] [17] [18] [19] [20] , and less than 5% underwent surgery under 7 days. Younger patient age, female sex, a Charlson-Deyo score of 1 or 2, increased radiation dose, and performance of lobectomy over pneumonectomy were all associated with increased survival on multivariate analysis (see Table 2 ).
Discussion
NCRT followed by surgery is a potentially advantageous treatment option for selected patients with resectable stage IIIA NSCLC and limited mediastinal lymph node involvement. Despite the risk of increased postoperative complications associated with NCRT, there Figure 2 . Kaplan-Meier survival curve. Effect of interval between neoadjuvant chemoradiation and surgery on overall survival (OS). Categories 3-6, 6-9, and 9-12 wks indicates greater than the first number in the range and less than or equal to the last number in the range. *Univariate p values derived from comparisons of OS with that in the 0 to 3 weeks category; **Multivariate p values derived from comparisons OS with that in the 0 to less than 3 weeks category. are very little data to support a specific interval after completion of NCRT during which surgery should be performed. 3, 21 In an effort to optimize the outcomes of trimodality therapy for patients with locally advanced NSCLC, this analysis sought to utilize a large nationally representative cancer database to define the optimal interval for trimodality therapy. The results of this study demonstrated a median ITS of 40 days, with 41.6% of patients (n ¼ 675) at more than 6 weeks between NCRT and surgery. This interval is outside the upper limit of 5 weeks after completion of radiation described in a major randomized prospective clinical trial by Albain et al. 3, 5 In our survival analysis, waiting longer than 6 weeks after completion of NCRT was associated with decreased OS. Radiation dose is a continuous variable and the HR is reported in units of cGy. OS, overall survival; HR, hazard ratio; CI, confidence interval; NCRT, neoadjuvant chemoradiation; ITS, interval to surgery.
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On univariate analysis, those with an ITS of greater than 6 weeks and less than or equal to 9 weeks trended toward decreased OS compared with those in the 0 to 3 weeks category. However, univariate analysis did not account for the fact that a significantly higher percentage of patients in the greater than 6 weeks and less than or equal to 9 weeks category had a lobectomy instead of a pneumonectomy. Considering that receipt of a lobectomy was found to be associated with an increased OS compared with receipt of a pneumonectomy (see Table 2 ), the survival outcomes of those in the greater than 6 weeks and less than or equal to 9 weeks category may have been inflated on univariate analysis. Multivariable analysis accounted for the fact that receipt of a lobectomy were associated with better survival outcomes than receipt of a pneumonectomy and demonstrated that the correlation between lower OS and an ITS of greater than 6 weeks and less than or equal to 9 weeks was significant. As expected, those with an ITS of greater than 9 weeks and less than or equal to 12 weeks demonstrated significantly worse OS on both univariate and multivariate analysis. Interestingly, patients who had surgery 0 to 3 weeks after NCRT had the highest median OS compared with the other study quartiles. Most (75%) had surgery later than 2 weeks after NCRT, with fewer than 5% having an operation within 1 week of NCRT. The observation does not appear to support lung resection less than 2 weeks after NCRT. Results from several randomized trials suggest that performing surgery immediately after radiation therapy without an appropriate recovery period may be detrimental. 3, 7 Additionally, it should be noted that the 0 to 3 weeks quartile had the highest percentage of private insurance holders as well as metropolitan area dwellers, suggesting that this cohort was at an advantage socioeconomically. Considering that previous studies have shown that socioeconomically disadvantaged patients were more likely to have inferior survival regardless of treatment received, this may partly account for the higher median OS observed in this group. 22, 23 This analysis demonstrated a trend toward increased 90-day mortality in patients with an ITS of longer than 6 weeks. These results suggest that waiting longer than 6 weeks to have surgery after NCRT may negatively affect both perioperative mortality and OS. This finding concurs with prior data that recommend an ITS after NCRT of less than 8 weeks. 3, 5, 7 Minimizing the time between NCRT and surgery is thought to improve outcomes because it reduces the risks associated with operating in the presence of radiation pneumonitis. Although radiation may affect surgical outcomes anywhere between 3 and 12 weeks, it is particularly troublesome at the tail end of that interval, when a patient is at highest risk for the development of fibrosis, narrowing of the pulmonary vessels, microvascular thrombosis, and collagen deposition by fibroblasts into the interstitium, thus increasing the risk for postoperative complications. 8, 24, 25 Of note, those who had an ITS of longer than 6 weeks received greater total doses of radiation than those who had surgery earlier. Considering that a recent trial has shown that higher total doses of neoadjuvant radiation correlate with increased postoperative complications and non-cancer-related mortality, the differences in radiation dose among the quartiles may have affected survival outcomes. 26 To control for this bias, radiation dose was accounted for on the multivariate analysis in this study.
In the past, studies have demonstrated that NCRT may impair diffusion capacity of the lung for carbon monoxide. 27 Sparse observational data suggest that the impact of radiation on lung diffusion capacity resolves at 4 to 6 weeks after completion of therapy, which is why some recommend waiting a minimum of 4 to 6 weeks after completion NCRT to perform surgery. 13 However, there are no definitive studies demonstrating that 4 to 6 weeks is the optimal time period for the recovery of diffusion capacity, nor are there data showing that operating outside of this interval negatively affects functional or survival outcomes. In fact, in a study of patients with NSCLC treated with either radiation therapy alone or radiation therapy in addition to chemotherapy, improvements in diffusion capacity occurred at a rate of 1% per month for the first 2 years after treatment. 28 Although more studies are needed to clarify this finding, waiting for a measurable recovery of diffusion capacity after induction therapy may not be feasible. Additionally, it is uncertain whether waiting for pulmonary function to improve leads to decreased postoperative risk. 13 A study by Rivera et al. showed that although preoperative chemotherapy led to decreases in diffusion capacity, this did not correlate with clinical symptoms or significantly alter the percentage of patients who were considered surgical candidates. 29 Clearly, further studies are needed to characterize the recovery of pulmonary function after NCRT and whether this correlates with postoperative outcomes. Although our study does not address the recovery of diffusion capacity after NCRT because of the constraints of the NCDB, the results imply that waiting longer than 6 weeks after NCRT to perform surgery may be detrimental from a survival viewpoint. This suggests that the benefits of waiting longer than 6 weeks after NCRT for the recovery of diffusion capacity may be outweighed by the risks of developing radiation pneumonitis or fibrotic changes in the pulmonary infrastructure. 30 This point is supported by numerous studies demonstrating that clinically evident signs of radiation induced pulmonary dysfunction, including pneumonitis, generally occur at least one month after radiation. [31] [32] [33] The retrospective nature of this study limits our ability to further elucidate why patients with a longer ITS have lower survival rates, particularly because the indication for surgical delay is unknown. In an effort to exclude patients with complications after chemotherapy and radiation who underwent salvage resection instead of a curative-intent operation, we excluded patients with an ITS longer than 3 months. However, delayed surgery may also be the result of excessive preoperative waiting times on account of scheduling and communication difficulties or patient preference. 34, 35 There are several other limitations of this study. Information on why patients underwent a pneumonectomy as opposed to a lobectomy or a sublobar resection was not available. Additionally, no data on disease recurrence or disease specific survival were provided by the NCDB, and OS was the only measurement of outcome. Specific details related to tumor staging and perioperative/postoperative complications were also not available. Considering the retrospective nature of this study, selection bias in treatment allocation should be considered. Finally, a substantial limitation lies in the fact that the NCDB captures limited patient demographics and appropriate adjustment for performance status could not be made.
This study is unique in that it examines the effects of timing of surgery after concurrent NCRT on survival in patients with stage IIIA NSCLC with N2 involvement. Surprisingly, the existing data to support current clinical practices remain sparse. The results of this study demonstrate that a significant correlation may exist between OS and ITS, and that delaying surgery beyond 6 weeks after NCRT may negatively affect survival. Further prospective studies are needed to confirm these findings and determine the reasons for this correlation.
